ArticleAntimicrobial agents and chemotherapy2024
Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method.The Journal of antimicrobial chemotherapy · 2026Pooled it
- Significant Publications on Infectious Diseases Pharmacotherapy in 2024.Journal of pharmacy practice · 2026Review
- A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Sulbactam-Durlobactam in the Treatment of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Sulbactam-Durlobactam for Carbapenem-ResistantPathogens (Basel, Switzerland) · 2026Review
- A 4-methyl-substituted durlobactam analogue as a potential class-D oxacillinase inhibitor inFrontiers in bioinformatics · 2026Article
- Real-World Clinical Outcomes of Sulbactam-Durlobactam Against Carbapenem-ResistantInfection and drug resistance · 2026Article
- Successful Treatment of Carbapenem-ResistantInfection and drug resistance · 2026Article
- New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam.Antimicrobial agents and chemotherapy · 2025Review
- Sulbactam-durlobactam in combination with aztreonam and carbapenems against carbapenem-resistantJournal of clinical microbiology · 2025Article
- Review
- Article
- ComparativeJAC-antimicrobial resistance · 2025Article
- AMRrounds: Carbapenem-resistantJAC-antimicrobial resistance · 2025Article
- Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?Antimicrobial agents and chemotherapy · 2025Article
- Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Novel Antibiotics for Gram-Negative Nosocomial Pneumonia.Antibiotics (Basel, Switzerland) · 2024Review
- Unveiling the Secrets ofInternational journal of molecular sciences · 2024Review
- Article
- Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates ofAntimicrobial agents and chemotherapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Infections caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.